BioSpace News Archive

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, announced the appointment of Marni Kottle as senior vice president of Corporate Communications and Investor Relations.

The global cerebral palsy market is picking up steam due to increasing awareness about the condition amongst parents.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per a survey by Fact.MR, the global calprotectin serum immunoassay market is poised to witness a steady growth during the forecast period 2021 to 2031.

Biophytis SA, a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, announces its management will participate and meet with investors at the following upcoming events and conferences:

Munich-based digital health company Temedica and healthcare company Roche Pharma AG have announced a joint collaboration in the field of digital support for multiple sclerosis patients.

Exact Sciences Corp., a global leader in cancer diagnostics, announced that it has entered into a collaboration agreement with the National Surgical Adjuvant Breast and Bowel Project, a cooperative group founded by the National Cancer Institute.

NanoViricides, Inc., a global leader in nanomedicines against viruses, announced that it has completed the process of licensing the human Coronavirus field for drug development and commercialization from TheraCour Pharma, Inc.

Vanqua Bio, a Chicago-based biopharmaceutical company dedicated to discovering and developing next-generation medicines for neurodegenerative diseases, announced that it closed an $85 million Series B financing round, led by Omega Funds.

Zimmer Biomet Holdings, Inc., a global medical technology leader, announced key appointments to the “NewCo” leadership team, including Richard J. Heppenstall as Executive Vice President and Chief Financial Officer.

Nimbus Therapeutics today announced dosing of patients in the Phase 2b study of the company’s oral allosteric TYK2 inhibitor.